Frontlight ResearchEarly access
Active, not recruitingNo phase
Efficacy and Influencing Factors of Repeated Low-level Red-light in Myopia
Key facts
- Who runs it
- Ruihua Wei
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 3,000 people, planned
- Started
- 28 Sept 2020
- Expected to end
- 28 Jul 2030
- Type of study
- Observational, 4 groups
- Treatments tested
- Red Light
- Record updated
- 8 September 2025
Who can take part
- Age
- 5 years to 16 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Ages 5 to 16, gender unrestricted
- RLRL device usage duration of one year or more
Who cannot take part
- Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
- With congenital eye disease, such as congenital cataract, congenital retinal disease
- Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
- Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
- Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
- Children with obvious strabismus and amblyopia
- Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP \>21mmHg or binocular IOP difference ≥5mmHg)
- Optic nerve damage or congenital optic nerve dysfunction
- Can not be regularly checked
- The adjustment range is less than 8D or obvious near difficulties
- Other reasons researchers think it is not suitable for inclusion in researchers
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the long-term efficacy of repeated low-level red-light (RLRL) therapy in the prevention and control of myopia in children, and to analyze the key factors influencing its efficacy (such as individual differences and compliance), with the aim of providing evidence-based support for the optimization of clinical myopia prevention and control strategies.
The 4 groups in the trial
- The RLRL-1year Group
use red light 1 year
Treatment: Red Light
- The RLRL-2years Group
Treatment: Red Light
- The RLRL-3years Group
Treatment: Red Light
- The RLRL-more than 3 years
use the RLRL-more than 3 years
Treatment: Red Light
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Study on the Long-term Efficacy Evaluation and Influencing Factors of Repeated Low-level Red-light Therapy in Myopia Prevention and Control in Children
- Record updated
- 8 September 2025